<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754987</url>
  </required_header>
  <id_info>
    <org_study_id>12D.424</org_study_id>
    <nct_id>NCT01754987</nct_id>
  </id_info>
  <brief_title>A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective</brief_title>
  <official_title>Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment
      with sorafenib versus treatment with sorafenib alone in subjects with metastatic
      hepatocellular carcinoma. The phase I aspect will assess the safety and efficacy of the
      concurrent treatments and the phase II aspect will utilize CT (computer-tomography) scans to
      assess overall tumor response rate and evaluate disease progression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous Ascorbic Acid (Vitamin C) is a widely used alternative cancer treatment. This
      trial will study an intravenous Vitamin C treatment for persons with liver cancer that has
      spread, who are also receiving Sorafenib (a standard cancer drug), to see whether the
      combination of Vitamin C and Sorafenib is safe and well tolerated. Phase I will involve 6
      persons who will receive the Vitamin C for 8 weeks to more specifically assess the safety of
      getting Vitamin C in combination with Sorafenib. Phase II will be randomized to receive
      either Vitamin C plus Sorafenib or Sorafenib alone for 16 weeks. If Vitamin C has a
      beneficial effect on tumour cells, patients may experience a regression of tumor or tumor
      markers. Additional benefits include scans at no charge to the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Experience Serious Adverse Events.</measure>
    <time_frame>16 weeks +/- 2 weeks</time_frame>
    <description>The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with sorafenib therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE)v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Tumor Response Rate</measure>
    <time_frame>16 weeks +/- 2 weeks</time_frame>
    <description>To utilize CT or PET/CT scans to assess overall tumor response rate (complete) in subjects with advanced metastatic hepatocellular cancer treated with the combination of ascorbic acid and sorafenib versus sorafenib alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value Collected Using the Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument</measure>
    <time_frame>16 weeks +/- 2 weeks</time_frame>
    <description>To evaluate quality of life using Functional Assessment of Cancer Therapy-General (FACT-G) quality assessment instrument. The FACT-G questionnaire will be used to assess quality-of-life longitudinally. Quality-of-life scores obtained from the FACT-G will be summarized at multiple time points. Five-point scale from 0 (not at all) to 4 (very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Are Alive After 15 Weeks of Treatment.</measure>
    <time_frame>15 weeks+</time_frame>
    <description>To evaluate duration of tumor response and progression-free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Metastatic Hepatocellular Carcinoma</condition>
  <condition>Advanced Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Ascorbic Acid + Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sorafenib: taken daily (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid + Sorafenib</intervention_name>
    <arm_group_label>Ascorbic Acid + Sorafenib</arm_group_label>
    <other_name>Vitamin C</other_name>
    <other_name>Ascorbate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <arm_group_label>Sorafenib alone</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Metastatic hepatocellular carcinoma

          -  G6PD (glucose-6-phosphate dehydrogenase) status &gt; lower limit of normal

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          -  Laboratory at baseline evaluation for inclusion in the study: creatinine ≤1.5X upper
             limit (if the creatinine is elevated, but ≤1.5X the ULN, a 24 hour creatinine
             clearance will be obtained); transaminase (AST/ALT) ≤2.0X upper limit of normal;
             bilirubin levels ≥ 2 mg/dL; ANC ≥1,500/mm3; Hemoglobin &gt; 8g/dL; platelet ≥ 100,000/mm3

          -  Women of childbearing potential will confirm a negative pregnancy test and must
             practice effective contraception during the study.

          -  Willing and able to provide informed consent and participate in the study procedures.

        Exclusion Criteria:

          -  Patients with evidence of a significant current psychiatric disorder that would
             prevent completion of the study as determined by the PI will not be allowed to
             participate.

          -  Co-morbid medical condition that would affect survival or tolerance as determined by
             the PI. This includes patients who have not fully recovered from toxicities associated
             with prior therapy. It also includes subjects who, as determined by the PI, are at
             risk of experiencing fluid overload (i.e., congestive heart failure).

          -  Patients who currently abuse alcohol or drugs.

          -  Patients with known glomerular filtration rate of &lt;60ml/min or with nephrotic range
             proteinuria.

          -  Pregnant or lactating women

          -  Enrollment in active clinical trial/ experimental therapy or IND study within the
             prior 30 days.

          -  Contraindication for CT or PET/CT as per the PI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A Monti, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. doi: 10.1371/journal.pone.0029794. Epub 2012 Jan 17.</citation>
    <PMID>22272248</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <results_first_submitted>June 25, 2018</results_first_submitted>
  <results_first_submitted_qc>July 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2018</results_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamins</keyword>
  <keyword>Malignant Tumor, Tumour</keyword>
  <keyword>Integrative Medicine</keyword>
  <keyword>Complementary Medicine</keyword>
  <keyword>Alternative Medicine Antioxidants</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Protective Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Growth Substances</keyword>
  <keyword>Antineoplastic Agents, Phytogenic</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Radiation-Sensitizing Agents</keyword>
  <keyword>Liver Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ascorbic Acid + Sorafenib</title>
          <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)
Ascorbic Acid + Sorafenib</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib Alone</title>
          <description>Sorafenib: taken daily (oral)
Sorafenib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The trial was terminated prematurely. No patients were accrued to the Sorafenib arm. Data were not collected</population>
      <group_list>
        <group group_id="B1">
          <title>Ascorbic Acid + Sorafenib</title>
          <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)
Ascorbic Acid + Sorafenib</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib Alone</title>
          <description>Sorafenib: taken daily (oral)
Sorafenib</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Experience Serious Adverse Events.</title>
        <description>The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with sorafenib therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE)v4.0</description>
        <time_frame>16 weeks +/- 2 weeks</time_frame>
        <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid + Sorafenib</title>
            <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)
Ascorbic Acid + Sorafenib</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib Alone</title>
            <description>Sorafenib: taken daily (oral)
Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experience Serious Adverse Events.</title>
          <description>The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with sorafenib therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE)v4.0</description>
          <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Tumor Response Rate</title>
        <description>To utilize CT or PET/CT scans to assess overall tumor response rate (complete) in subjects with advanced metastatic hepatocellular cancer treated with the combination of ascorbic acid and sorafenib versus sorafenib alone.</description>
        <time_frame>16 weeks +/- 2 weeks</time_frame>
        <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid + Sorafenib</title>
            <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)
Ascorbic Acid + Sorafenib</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib Alone</title>
            <description>Sorafenib: taken daily (oral)
Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Tumor Response Rate</title>
          <description>To utilize CT or PET/CT scans to assess overall tumor response rate (complete) in subjects with advanced metastatic hepatocellular cancer treated with the combination of ascorbic acid and sorafenib versus sorafenib alone.</description>
          <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value Collected Using the Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument</title>
        <description>To evaluate quality of life using Functional Assessment of Cancer Therapy-General (FACT-G) quality assessment instrument. The FACT-G questionnaire will be used to assess quality-of-life longitudinally. Quality-of-life scores obtained from the FACT-G will be summarized at multiple time points. Five-point scale from 0 (not at all) to 4 (very much)</description>
        <time_frame>16 weeks +/- 2 weeks</time_frame>
        <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid + Sorafenib</title>
            <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)
Ascorbic Acid + Sorafenib</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib Alone</title>
            <description>Sorafenib: taken daily (oral)
Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value Collected Using the Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument</title>
          <description>To evaluate quality of life using Functional Assessment of Cancer Therapy-General (FACT-G) quality assessment instrument. The FACT-G questionnaire will be used to assess quality-of-life longitudinally. Quality-of-life scores obtained from the FACT-G will be summarized at multiple time points. Five-point scale from 0 (not at all) to 4 (very much)</description>
          <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Are Alive After 15 Weeks of Treatment.</title>
        <description>To evaluate duration of tumor response and progression-free survival</description>
        <time_frame>15 weeks+</time_frame>
        <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid + Sorafenib</title>
            <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)
Ascorbic Acid + Sorafenib</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib Alone</title>
            <description>Sorafenib: taken daily (oral)
Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Are Alive After 15 Weeks of Treatment.</title>
          <description>To evaluate duration of tumor response and progression-free survival</description>
          <population>The trial was closed early due to lack of accrual. The data were not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ascorbic Acid + Sorafenib</title>
          <description>Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
Dosage:
Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)
Ascorbic Acid + Sorafenib</description>
        </group>
        <group group_id="E2">
          <title>Sorafenib Alone</title>
          <description>Sorafenib: taken daily (oral)
Sorafenib</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nosebleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Low Platelet count</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Monti</name_or_title>
      <organization>Sidney Kimmel Cancer Center at Thomas Jefferson University</organization>
      <phone>215 955-2221</phone>
      <email>daniel.monti@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

